Morphosys Ag (NASDAQ:MPSYY) Upgraded to Overweight by J P Morgan Chase & Co

Morphosys Ag (NASDAQ:MPSYY) was upgraded by equities research analysts at J P Morgan Chase & Co from a “neutral” rating to an “overweight” rating in a report issued on Friday, October 6th, The Fly reports.

Shares of Morphosys Ag (NASDAQ:MPSYY) opened at 43.94 on Friday. The firm’s market capitalization is $2.55 billion. Morphosys Ag has a 52-week low of $21.55 and a 52-week high of $44.97. The company has a 50 day moving average of $39.87 and a 200 day moving average of $35.21.

COPYRIGHT VIOLATION NOTICE: “Morphosys Ag (NASDAQ:MPSYY) Upgraded to Overweight by J P Morgan Chase & Co” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/18/morphosys-ag-mpsyy-raised-to-overweight-at-j-p-morgan-chase-co.html.

Morphosys Ag Company Profile

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company’s operating segments include Proprie

Shares of Morphosys Ag (NASDAQ:MPSYY) opened at 43.94 on Friday. The firm’s market capitalization is $2.55 billion. Morphosys Ag has a 52-week low of $21.55 and a 52-week high of $44.97. The company has a 50 day moving average of $39.87 and a 200 day moving average of $35.21.

COPYRIGHT VIOLATION NOTICE: “Morphosys Ag (NASDAQ:MPSYY) Upgraded to Overweight by J P Morgan Chase & Co” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://ledgergazette.com/2017/10/18/morphosys-ag-mpsyy-raised-to-overweight-at-j-p-morgan-chase-co.html.

Morphosys Ag Company Profile

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company’s operating segments include Proprietary Development and Partnered Discovery.

The Fly

Receive News & Ratings for Morphosys Ag Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys Ag and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply